HOME > TOP STORIES

TOP STORIES

BUSINESS Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan

September 10, 2019
BUSINESS To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant

September 9, 2019
BUSINESS Labor Union Urges MSD Japan to Make Convincing Case on Job Cuts

September 6, 2019
REGULATORY In Fight against AMR, Japan Set to Forge Prefectural Networks to Push Proper Antibiotic Use

September 5, 2019
BUSINESS Roche/Chugai’s Rozlytrek, AstraZeneca COPD Combos and More Hit Shelves

September 5, 2019
BUSINESS Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing

September 4, 2019
BUSINESS Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology

September 3, 2019
BUSINESS Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values

September 2, 2019
TRENDS Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up

August 30, 2019
REGULATORY MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug

August 30, 2019
ORGANIZATION Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs

August 29, 2019
REGULATORY Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4

August 28, 2019
REGULATORY Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen

August 28, 2019
REGULATORY Tagrisso to Face 15% Price Cut in November Because It Sold Too Well

August 27, 2019
ORGANIZATION Kenporen Proposes Excluding OTC-Like Pollinosis Drugs from Health Coverage, Expecting Annual Savings of 60 Billion Yen

August 26, 2019
REGULATORY Japan to Set Up Dedicated Team to Expedite Review of Sakigake-Designated Cell/Gene Therapies

August 23, 2019
REGULATORY Tecentriq Wins Japan Nod for SCLC as 1st Checkpoint Drug for This Use

August 23, 2019
BUSINESS Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey

August 22, 2019
BUSINESS Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers

August 21, 2019
REGULATORY No PMP for Tecentriq, but Prices Rise for All 5 Checkpoint Drugs in Tax Hike Re-Pricing

August 21, 2019

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…